Septerna (NASDAQ:SEPN) Trading Up 12.2% – Here’s Why

Septerna, Inc. (NASDAQ:SEPN)’s share price rose 12.2% during mid-day trading on Thursday . The stock traded as high as $17.62 and last traded at $17.45. Approximately 106,955 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 197,869 shares. The stock had previously closed at $15.55.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. started coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective for the company. Finally, TD Cowen initiated coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating on the stock.

Septerna Price Performance

The stock has a 50-day moving average of $21.88.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Septerna stock. Rhumbline Advisers bought a new position in shares of Septerna, Inc. (NASDAQ:SEPN) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 19,995 shares of the company’s stock, valued at approximately $458,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.